Simvastatin inhibits PDGF-induced DNA synthesis in human glomerular mesangial cells

Giuseppe Grandaliano, Purba Biswas, Goutam Ghosh-choudhury, Hanna E. Abboud

Research output: Contribution to journalArticle

106 Citations (Scopus)

Abstract

Simvastatin inhibits PDGF-induced DNA synthesis in human glomerular mesangial cells. Inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMGCoA) reductase ameliorate glomerular pathology and renal dysfunction in different models of glomerular disease. This effect has generally been attributed to a decrease in the circulating levels of cholesterol. Focal or diffuse mesangial cell proliferation is a common feature of glomerular pathology. There is now evidence from studies in vitro and in vivo that platelet-derived growth factor (PDGF) is an important mediator of glomerular hypercellularity. The activity of HMGCoA reductase has previously been shown to be a requirement for cell growth. In the present study, we examined the effect of simvastatin, an HMGCoA reductase inhibitor, on PDGF-induced DNA synthesis and PDGF B chain gene expression in human glomerular mesangial cells. In addition, we investigated the effect of simvastatin on phospholipase C (PLC) and protein kinase C (PKC) activation stimulated by PDGF. We demonstrate that treatment of the cells with simvastatin completely inhibits PDGF-induced DNA synthesis. This inhibition is reversed by mevalonate but not by cholesterol or farnesol, two major metabolites of the mevalonate pathway. On the other hand inhibition of HMGCoA reductase does not influence PDGF-induced activation of PLC and PKC, or PDGF B chain gene expression. These data suggest that simvastatin acts at a late step in the PDGF mitogenic pathway without interfering with other early cellular responses elicited by this growth factor. These studies also raise the possibility that the ameliorative effect of HMGCoA reductase inhibitors on glomerular pathology may be mediated, at least in part, by a direct cellular effect.

Original languageEnglish (US)
Pages (from-to)503-508
Number of pages6
JournalKidney International
Volume44
Issue number3
StatePublished - Sep 1993

Fingerprint

Simvastatin
Mesangial Cells
Platelet-Derived Growth Factor
Coenzyme A
Oxidoreductases
DNA
Proto-Oncogene Proteins c-sis
Mevalonic Acid
Type C Phospholipases
Pathology
Protein Kinase C
Cholesterol
Farnesol
Gene Expression
Intercellular Signaling Peptides and Proteins
Cell Proliferation
Kidney
Growth

ASJC Scopus subject areas

  • Nephrology

Cite this

Simvastatin inhibits PDGF-induced DNA synthesis in human glomerular mesangial cells. / Grandaliano, Giuseppe; Biswas, Purba; Ghosh-choudhury, Goutam; Abboud, Hanna E.

In: Kidney International, Vol. 44, No. 3, 09.1993, p. 503-508.

Research output: Contribution to journalArticle

Grandaliano, Giuseppe ; Biswas, Purba ; Ghosh-choudhury, Goutam ; Abboud, Hanna E. / Simvastatin inhibits PDGF-induced DNA synthesis in human glomerular mesangial cells. In: Kidney International. 1993 ; Vol. 44, No. 3. pp. 503-508.
@article{a6eb1b98e2c3412ab1e1707f5c38954d,
title = "Simvastatin inhibits PDGF-induced DNA synthesis in human glomerular mesangial cells",
abstract = "Simvastatin inhibits PDGF-induced DNA synthesis in human glomerular mesangial cells. Inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMGCoA) reductase ameliorate glomerular pathology and renal dysfunction in different models of glomerular disease. This effect has generally been attributed to a decrease in the circulating levels of cholesterol. Focal or diffuse mesangial cell proliferation is a common feature of glomerular pathology. There is now evidence from studies in vitro and in vivo that platelet-derived growth factor (PDGF) is an important mediator of glomerular hypercellularity. The activity of HMGCoA reductase has previously been shown to be a requirement for cell growth. In the present study, we examined the effect of simvastatin, an HMGCoA reductase inhibitor, on PDGF-induced DNA synthesis and PDGF B chain gene expression in human glomerular mesangial cells. In addition, we investigated the effect of simvastatin on phospholipase C (PLC) and protein kinase C (PKC) activation stimulated by PDGF. We demonstrate that treatment of the cells with simvastatin completely inhibits PDGF-induced DNA synthesis. This inhibition is reversed by mevalonate but not by cholesterol or farnesol, two major metabolites of the mevalonate pathway. On the other hand inhibition of HMGCoA reductase does not influence PDGF-induced activation of PLC and PKC, or PDGF B chain gene expression. These data suggest that simvastatin acts at a late step in the PDGF mitogenic pathway without interfering with other early cellular responses elicited by this growth factor. These studies also raise the possibility that the ameliorative effect of HMGCoA reductase inhibitors on glomerular pathology may be mediated, at least in part, by a direct cellular effect.",
author = "Giuseppe Grandaliano and Purba Biswas and Goutam Ghosh-choudhury and Abboud, {Hanna E.}",
year = "1993",
month = "9",
language = "English (US)",
volume = "44",
pages = "503--508",
journal = "Kidney International",
issn = "0085-2538",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - Simvastatin inhibits PDGF-induced DNA synthesis in human glomerular mesangial cells

AU - Grandaliano, Giuseppe

AU - Biswas, Purba

AU - Ghosh-choudhury, Goutam

AU - Abboud, Hanna E.

PY - 1993/9

Y1 - 1993/9

N2 - Simvastatin inhibits PDGF-induced DNA synthesis in human glomerular mesangial cells. Inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMGCoA) reductase ameliorate glomerular pathology and renal dysfunction in different models of glomerular disease. This effect has generally been attributed to a decrease in the circulating levels of cholesterol. Focal or diffuse mesangial cell proliferation is a common feature of glomerular pathology. There is now evidence from studies in vitro and in vivo that platelet-derived growth factor (PDGF) is an important mediator of glomerular hypercellularity. The activity of HMGCoA reductase has previously been shown to be a requirement for cell growth. In the present study, we examined the effect of simvastatin, an HMGCoA reductase inhibitor, on PDGF-induced DNA synthesis and PDGF B chain gene expression in human glomerular mesangial cells. In addition, we investigated the effect of simvastatin on phospholipase C (PLC) and protein kinase C (PKC) activation stimulated by PDGF. We demonstrate that treatment of the cells with simvastatin completely inhibits PDGF-induced DNA synthesis. This inhibition is reversed by mevalonate but not by cholesterol or farnesol, two major metabolites of the mevalonate pathway. On the other hand inhibition of HMGCoA reductase does not influence PDGF-induced activation of PLC and PKC, or PDGF B chain gene expression. These data suggest that simvastatin acts at a late step in the PDGF mitogenic pathway without interfering with other early cellular responses elicited by this growth factor. These studies also raise the possibility that the ameliorative effect of HMGCoA reductase inhibitors on glomerular pathology may be mediated, at least in part, by a direct cellular effect.

AB - Simvastatin inhibits PDGF-induced DNA synthesis in human glomerular mesangial cells. Inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMGCoA) reductase ameliorate glomerular pathology and renal dysfunction in different models of glomerular disease. This effect has generally been attributed to a decrease in the circulating levels of cholesterol. Focal or diffuse mesangial cell proliferation is a common feature of glomerular pathology. There is now evidence from studies in vitro and in vivo that platelet-derived growth factor (PDGF) is an important mediator of glomerular hypercellularity. The activity of HMGCoA reductase has previously been shown to be a requirement for cell growth. In the present study, we examined the effect of simvastatin, an HMGCoA reductase inhibitor, on PDGF-induced DNA synthesis and PDGF B chain gene expression in human glomerular mesangial cells. In addition, we investigated the effect of simvastatin on phospholipase C (PLC) and protein kinase C (PKC) activation stimulated by PDGF. We demonstrate that treatment of the cells with simvastatin completely inhibits PDGF-induced DNA synthesis. This inhibition is reversed by mevalonate but not by cholesterol or farnesol, two major metabolites of the mevalonate pathway. On the other hand inhibition of HMGCoA reductase does not influence PDGF-induced activation of PLC and PKC, or PDGF B chain gene expression. These data suggest that simvastatin acts at a late step in the PDGF mitogenic pathway without interfering with other early cellular responses elicited by this growth factor. These studies also raise the possibility that the ameliorative effect of HMGCoA reductase inhibitors on glomerular pathology may be mediated, at least in part, by a direct cellular effect.

UR - http://www.scopus.com/inward/record.url?scp=0027181537&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027181537&partnerID=8YFLogxK

M3 - Article

C2 - 8231022

AN - SCOPUS:0027181537

VL - 44

SP - 503

EP - 508

JO - Kidney International

JF - Kidney International

SN - 0085-2538

IS - 3

ER -